Sanofi and Glax­o­SmithK­line: Those PhI­II Covid-19 vac­cine re­sults you’ve been wait­ing for? Wait longer (but here's some boost­er da­ta)

We will now have to wait un­til 2022 to find out whether Sanofi and Glax­o­SmithK­line have an ef­fec­tive re­com­bi­nant vac­cine against Covid-19.

The two phar­ma gi­ants re­vealed that their Phase III tri­al isn’t quite ready for a read­out. Mean­while, they seem to have more hope in the boost­er ap­pli­ca­tion of their can­di­date, tout­ing pos­i­tive pre­lim­i­nary da­ta sug­gest­ing that it spurred an in­crease in neu­tral­iz­ing an­ti­bod­ies in all pa­tients — whether they re­ceived mR­NA or ade­n­ovirus-based shots as the pri­ma­ry vac­cines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER